These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 20872965)

  • 1. Roles of liver innate immune cells in nonalcoholic fatty liver disease.
    Zhan YT; An W
    World J Gastroenterol; 2010 Oct; 16(37):4652-60. PubMed ID: 20872965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of liver-infiltrating CD3+CD56+ natural killer T cells in the pathogenesis of nonalcoholic fatty liver disease.
    Tajiri K; Shimizu Y; Tsuneyama K; Sugiyama T
    Eur J Gastroenterol Hepatol; 2009 Jun; 21(6):673-80. PubMed ID: 19318971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of Hepatic Innate and Innate-Like Lymphocytes in Nonalcoholic Steatohepatitis.
    Chen Y; Tian Z
    Front Immunol; 2020; 11():1500. PubMed ID: 32765518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease.
    De Vito R; Alisi A; Masotti A; Ceccarelli S; Panera N; Citti A; Salata M; Valenti L; Feldstein AE; Nobili V
    Int J Mol Med; 2012 Jul; 30(1):49-56. PubMed ID: 22505182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
    Ota T
    Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis.
    Kremer M; Thomas E; Milton RJ; Perry AW; van Rooijen N; Wheeler MD; Zacks S; Fried M; Rippe RA; Hines IN
    Hepatology; 2010 Jan; 51(1):130-41. PubMed ID: 20034047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dietary fatty acids modulate antigen presentation to hepatic NKT cells in nonalcoholic fatty liver disease.
    Hua J; Ma X; Webb T; Potter JJ; Oelke M; Li Z
    J Lipid Res; 2010 Jul; 51(7):1696-703. PubMed ID: 20185414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Macrophage heterogeneity role in NAFLD and NASH disease progression].
    Yang T; Wang X; Jiang LF; Li J
    Zhonghua Gan Zang Bing Za Zhi; 2023 Jul; 31(7):770-775. PubMed ID: 37580264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T Cell Subsets and Natural Killer Cells in the Pathogenesis of Nonalcoholic Fatty Liver Disease.
    Gebru YA; Gupta H; Kim HS; Eom JA; Kwon GH; Park E; Jeong JJ; Won SM; Sharma SP; Ganesan R; Kim DJ; Suk KT
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of vitamin E in nonalcoholic fatty liver disease.
    Nagashimada M; Ota T
    IUBMB Life; 2019 Apr; 71(4):516-522. PubMed ID: 30592129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis.
    Sharma M; Mitnala S; Vishnubhotla RK; Mukherjee R; Reddy DN; Rao PN
    J Clin Exp Hepatol; 2015 Jun; 5(2):147-58. PubMed ID: 26155043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of nonalcoholic steatohepatitis (NASH).
    Ma X; Li Z
    Chin J Dig Dis; 2006; 7(1):7-11. PubMed ID: 16412031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major roles of kupffer cells and macrophages in NAFLD development.
    Park SJ; Garcia Diaz J; Um E; Hahn YS
    Front Endocrinol (Lausanne); 2023; 14():1150118. PubMed ID: 37274349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The common marmoset as a model for the study of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Kramer JA; Grindley J; Crowell AM; Makaron L; Kohli R; Kirby M; Mansfield KG; Wachtman LM
    Vet Pathol; 2015 Mar; 52(2):404-13. PubMed ID: 24913270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic fatty liver disease: biochemical and therapeutic considerations.
    Patrick-Melin AJ; Kalinski MI; Kelly KR; Haus JM; Solomon TP; Kirwan JP
    Ukr Biokhim Zh (1999); 2009; 81(5):16-25. PubMed ID: 20387643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis.
    Nagata K; Suzuki H; Sakaguchi S
    J Toxicol Sci; 2007 Dec; 32(5):453-68. PubMed ID: 18198478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Cha JY; Kim DH; Chun KH
    Lab Anim Res; 2018 Dec; 34(4):133-139. PubMed ID: 30671098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innate immunity in the liver.
    Li Z; Diehl AM
    Curr Opin Gastroenterol; 2003 Nov; 19(6):565-71. PubMed ID: 15703606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.